Biomarker Scores Pinpoint Diets High in UPFs
New poly-metabolite scores worked as objective measures of ultraprocessed food (UPF) intake and could curb reliance on self-report data in studies. METHODOLOGY: Using ultra–high performance liquid chromatography with tandem mass spectrometry, researchers analyzed existing metabolite data from blood and urine specimens provided by 718 individuals aged 50-74 years who participated in various clinical trials.
They then used machine learning to identify metabolic patterns associated with high UPF consumption to estimate UPF-metabolite correlations and build poly-metabolite scores of UPF uptake.
They tested the scores in a post hoc analysis of a previously conducted small randomized, controlled crossover trial of 20 adults who ate a diet high in UPF (80% of energy consumed) and a diet without UPF for 2 weeks each in random order. TAKEAWAY: The poly-metabolite scores differentiated, within individual, between the diets that were 80% and 0% energy from UPF.
The mean UPF intake was 50% energy, and this correlated with serum and 24-hour urine metabolites.
The findings need to be replicated in other age groups and populations.
Research on the prospective association between UPF-correlated metabolites, poly-metabolite scores, and disease risk is warranted. IN PRACTICE:
'Limitations of self-reported diet are well known,' lead investigator Erikka Loftfield, PhD, of the US National Cancer Institute said in an accompanying press release. 'Metabolomics provides an exciting opportunity to not only improve our methods for objectively measuring complex exposures like diet and intake of ultraprocessed foods, but also to understand the mechanisms by which diet might be impacting health.' SOURCE:
The study led by Loftfield was published in PLOS Medicine . LIMITATIONS:
Study participants were older US adults whose diets may vary from other populations. Poly-metabolite scores should be evaluated and iteratively improved in populations with diverse diets and a wide range of UPF intake. DISCLOSURES:
The research leading to these results received funding from the National Institutes of Health (NIH) Intramural Research Program at the National Cancer Institute and National Institute of Diabetes and Digestive and Kidney Diseased, as well as Fundação de Amparo à Pesquisa do Estado de São Paulo. Only one coauthor declared having competing interests, as noted in the paper.
Credit
Lead image: Rimidolove/Dreamstime
Medscape Medical News © 2025 WebMD, LLC
Cite this: Biomarker Scores Pinpoint Diets High in UPFs - Medscape - May 27, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Researchers trace drugs and diseases from DNA drifting through city air
DNA is in the air, and scientists are finally learning how to read it. In Dublin — a city known for its cozy pubs, flowing Guinness, and music that spills into cobbled streets — researchers have discovered something far less visible drifting through the air: traces of cannabis, poppy, and even psychedelic mushrooms. Not the plants themselves, but their DNA. A groundbreaking study by scientists at the University of Florida reveals that environmental DNA, or eDNA, vacuumed straight from the air, can offer stunning insights into the world around us. These range from identifying endangered wildlife and tracking human pathogens to detecting allergens and illicit drugs. 'The level of information that's available in environmental DNA is such that we're only starting to consider what the potential applications can be, from humans, to wildlife to other species that have implications for human health,' said David Duffy, Ph.D., lead author of the study and professor of wildlife disease genomics. Originally designed to study sea turtles, the technique developed by Duffy and his team has since transformed into a powerful tool for decoding the biological fingerprints of nearly any environment, including air, oceans, or forests. And all it takes is an air filter and a day in the lab to detect signs of nearly every living thing that's grown, passed through, or shed cells nearby. 'When we started, it seemed like it would be hard to get intact large fragments of DNA from the air. But that's not the case. We're actually finding a lot of informative DNA,' Duffy said in a release. 'That means you can study species without directly having to disturb them, without ever having to see them. It opens up huge possibilities to study all the species in an area simultaneously, from microbes and viruses all the way up to vertebrates like bobcats and humans, and everything in between.' In Dublin, researchers found DNA signatures from hundreds of sources, including human pathogens, bacteria, and allergens like peanut residue and pollen. In another striking demonstration of eDNA's potential, the researchers were able to trace the origins of bobcats and spiders by analyzing DNA captured from the air in a Florida forest. This powerful analysis also came with remarkable speed and efficiency. The team showed that a single researcher could process DNA from every species in a given area in just a day, using compact, low-cost equipment and cloud-based software. When trying to save and conserve wildlife, knowing where an animal originates from can be as important as knowing where it currently is. 'It seems like science fiction, but it's becoming science fact,' Duffy said. 'The technology is finally matching the scale of environmental problems.' The researchers say the implications of the study are vast. The method could help track disease outbreaks, identify endangered species, and even detect drug activity, all silently captured by the breeze. However, the same tools can also reveal sensitive human genetic information. The researchers have called for ethical guidelines to keep pace with the fast-moving science of study has been published in Nature, Ecology and Evolution.
Bloomberg
35 minutes ago
- Bloomberg
Israel-Backed Gaza Aid Group Suspends Operations for Second Day
An Israel- and US-backed mechanism to distribute food in Gaza suspended operations for a second day following a series of deadly incidents near its sites that drew international criticism. The Gaza Humanitarian Foundation, a Swiss-based nonprofit, launched in Gaza last week following a months-long Israeli blockade of the territory, and says it has handed out enough food staples for millions of meals. But the roll-out has been dogged by overcrowding and at least one incident in which Israeli forces, citing a security threat, fired toward Palestinians headed to a GHF aid center.
Medscape
38 minutes ago
- Medscape
Catching Resistance Early: Can New Breast Cancer Drug Help?
CHICAGO — Can spotting an emerging ESR1 mutation early and changing first-line drugs before progression improve outcomes in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2–negative advanced breast cancer? Interim findings from the SERENA-6 trial suggest that may be the case. Patients who switched from a first-line aromatase inhibitor to camizestrant, an investigational next-generation oral selective estrogen-receptor degrader, at the first signs of an emerging ESR1 mutation demonstrated significantly improved progression-free survival compared with those who continued their initial regimen. Notably, circulating tumor DNA (ctDNA) testing allowed investigators to identify ESR1 mutations, which emerge at the time of disease progression in about 40% of patients on a first-line aromatase inhibitor and lead to treatment resistance. Camizestrant, which has shown activity in patients who develop ESR1 mutations, helped improve first-line outcomes and has 'potential to become a new treatment strategy,' according to co-principal investigator Nicholas Turner, MD, PhD, professor and honorary consultant in medical oncology at the Institute of Cancer Research and Royal Marsden Hospital, London, England, who presented the findings at the American Society of Clinical Oncology (ASCO) 2025 annual meeting. Results were simultaneously published in The New England Journal of Medicine . This trial also demonstrated 'the clinical utility of ctDNA monitoring to detect and treat emerging resistance in breast cancer,' said Turner. While praising the findings, others were not convinced that the SERENA-6 results warrant a change in practice yet. 'Based on first-line progression-free survival alone, this could represent a new regulatory approval path,' said invited discussant Angela DeMichele, MD, of the University of Pennsylvania, Philadelphia. But, DeMichele cautioned, 'I cannot recommend the SERENA-6 strategy at this time.' One key reason, DeMichele noted, is that it's too early to tell whether this strategy improves overall survival. If camizestrant is approved based on progression-free survival and quality of life, DeMichele wondered, is it worth going through the ctDNA testing process if the drug doesn't help patients live longer? Paolo Tarantino, MD, a breast oncologist at Dana-Farber Cancer Institute and Harvard Medical School in Boston, echoed this sentiment in a tweet on X: 'Outstanding results, though not ready for clinical practice (yet),' adding that it will also be 'important to take into account financial, psychological, and systemic costs of the strategy.' Using ctDNA to Track Resistance In the study, 3256 patients who had received at least 6 months of treatment with aromatase inhibitors and CDK4/6 therapy (palbociclib, ribociclib, or abemaciclib) received ctDNA testing with Guardant360 CDx every 2-3 months at the time of routine staging exams. Overall, 315 patients who had an ESR1 mutation detected and had no radiologic evidence of disease progression were randomly assigned to either switch from the aromatase inhibitor to 75 mg of camizestrant daily (n = 157) or continue their aromatase inhibitor/CDK4/6 regimen (n = 158). (An additional 233 patients who had an ESR1 mutation detected were not included for a variety of reasons, including disease progression and consent withdrawal.) At the planned interim analysis, the median progression-free survival was 16.0 months in the camizestrant group and 9.2 months in the aromatase inhibitor group (adjusted hazard ratio [aHR], 0.44; P < .00001). At 24 months, only 5.4% of patients who had continued their initial first-line treatment had not progressed compared with 30% of patients on camizestrant. The progression-free survival findings were consistent across clinically relevant patient subgroups. Patients who switched to camizestrant also showed improved time to deterioration in global health status and quality of life — a median of 23.0 months vs 6.4 months in the aromatase group (aHR, 0.53). At the time of the interim analysis, overall survival data were immature, with 20 deaths in the camizestrant group and 19 in the aromatase inhibitor group (HR, 0.91; 95% CI, 0.48-1.73). As for time to second progression, there were 38 events in the camizestrant group and 47 events in the aromatase group, but the findings were also immature. As for adverse events, 60% of patients in the camizestrant group had a grade 3 or higher event, 10% of which were deemed serious compared with 46% in the aromatase group, 12% of which were serious. Neutropenia (45% vs 34%, respectively) and anemia (5% in both groups) were the most common grade 3 or higher adverse events. Only 1% of patients on camizestrant discontinued treatment due to adverse events. Overall, Turner concluded that 'for people with HR-positive advanced breast cancer, the results of SERENA-6 show that camizestrant plus CDK4/6 inhibitor could be a new treatment option to use at the point of ESR1 mutation detection during treatment with first-line aromatase inhibitor plus CDK4/6 inhibitor — but before the cancer grows.' Despite the promising findings, DeMichele highlighted several key unanswered questions and challenges. Notably, will this strategy lead to longer overall survival and demonstrate clinical utility? Overall survival and time to second progression are currently not known, DeMichele said. The trial did not address whether first-line treatment gains would be lost if camizestrant was given in the second-line setting after anatomic progression. DeMichele also noted the high cost and potential anxiety associated with serial ctDNA testing. Overall, 'the full complement of financial, psychological, and systemic costs is needed to fully assess utility and feasibility for implementation,' she added. SERENA-6 was supported by AstraZeneca. Turner disclosed consulting or advisory roles with AstraZeneca, Exact Sciences, Gilead Sciences, GlaxoSmithKline, Guardant Health, Inivata Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Relay Therapeutics, Repare Therapeutics, and Roche. DeMichele disclosed a consulting or advisory role with Pfizer.
